CD4+ T-Cell activity against SARS-CoV-2 S protein, RBD, and N protein;CD8+ T-Cell activity against SARS-CoV-2 S protein, RBD, and N protein;GMFR in IgG titer;GMFR in neutralizing antibody;GMT;GMT of S-specific, RBD-specific, and N-specific antibodies against 2019 novel coronavirus;Incidence and severity of solicited local reactogenicity AEs;Incidence and severity of solicited systemic reactogenicity AEs;Incidence and severity of unsolicited AEs;Incidence and severity of unsolicited AEs;Incidence of abnormal changes of laboratory safety examinations;Incidence of MAAEs and SAEs;Incidence of MAAEs and SAEs;Percentage of subjects who seroconverted;Seroconversion rate of neutralizing antibody;Vital Signs - Bradycardia;Vital Signs - Fever;Vital Signs - Hypertension;Vital Signs - Hypotension;Vital Signs - Respiratory Rate;Vital Signs - Tachycardia

CD4+ T-Cell activity against SARS-CoV-2 S protein, RBD, and N protein;CD8+ T-Cell activity against SARS-CoV-2 S protein, RBD, and N protein;GMFR in IgG titer;GMFR in neutralizing antibody;GMT;GMT of S-specific, RBD-specific, and N-specific antibodies against 2019 novel coronavirus;Incidence and severity of solicited local reactogenicity AEs;Incidence and severity of solicited systemic reactogenicity AEs;Incidence and severity of unsolicited AEs;Incidence and severity of unsolicited AEs;Incidence of abnormal changes of laboratory safety examinations;Incidence of MAAEs and SAEs;Incidence of MAAEs and SAEs;Percentage of subjects who seroconverted;Seroconversion rate of neutralizing antibody;Vital Signs - Bradycardia;Vital Signs - Fever;Vital Signs - Hypertension;Vital Signs - Hypotension;Vital Signs - Respiratory Rate;Vital Signs - Tachycardia

CD4+ T-Cell activity against SARS-CoV-2 S protein, RBD, and N protein;Vital Signs - Bradycardia;Incidence of MAAEs and SAEs;Vital Signs - Hypertension;Vital Signs - Hypotension;Incidence and severity of solicited local reactogenicity AEs;Vital Signs - Respiratory Rate;Incidence and severity of solicited systemic reactogenicity AEs;GMFR;Incidence and severity of unsolicited AEs;GMT of S-specific, RBD-specific, and N-specific antibodies against 2019 novel coronavirus;Incidence of MAAEs and SAEs;Percentage of subjects who seroconverted;Incidence and severity of unsolicited AEs;GMFR;Incidence of abnormal changes of laboratory safety examinations;GMT;Vital Signs - Fever;Seroconversion rate of neutralizing antibody;Vital Signs - Tachycardia;CD8+ T-Cell activity against SARS-CoV-2 S protein, RBD, and N protein

CD4+ T-Cell activity against SARS-CoV-2 S protein, RBD, and N protein;Vital Signs - Bradycardia;Incidence of MAAEs and SAEs;Vital Signs - Hypertension;Vital Signs - Hypotension;Incidence and severity of solicited local reactogenicity AEs;Vital Signs - Respiratory Rate;Incidence and severity of solicited systemic reactogenicity AEs;GMFR;Incidence and severity of unsolicited AEs;GMT of S-specific, RBD-specific, and N-specific antibodies against 2019 novel coronavirus;Incidence of MAAEs and SAEs;Percentage of subjects who seroconverted;Incidence and severity of unsolicited AEs;GMFR;Incidence of abnormal changes of laboratory safety examinations;GMT;Vital Signs - Fever;Seroconversion rate of neutralizing antibody;Vital Signs - Tachycardia;CD8+ T-Cell activity against SARS-CoV-2 S protein, RBD, and N protein